COEFFICIENT BIO, INC.

Based in the US, Coefficient Bio operates as a biotechnology company focused on enhancing biological processes through innovative solutions that cater to agriculture, healthcare, and environmental sectors. Coefficient Bio, Inc. specializes in biotechnology solutions that improve efficiency and effectiveness across multiple industries. Founded in New York, US in 2025, the company has engaged in one notable deal as of April 3, 2026, during which it was acquired by Anthropic PBC for USD 400 mn.

This acquisition is aimed at leveraging artificial intelligence capabilities for biological research and clinical applications. The company was founded by a team of experienced professionals who have previously worked in various sectors of technology and biotechnology. Coefficient Bio specializes in biotechnology solutions aimed at enhancing the efficiency and effectiveness of biological processes across various industries. The company's core offerings revolve around innovative bioproducts designed for applications in pharmaceuticals, agriculture, and environmental sustainability.

These products address critical challenges, such as improving crop yields, developing sustainable biofuels, and advancing medical therapies. Coefficient Bio's client base includes agricultural companies, research institutions, and healthcare providers, all seeking solutions to optimize their operations. The company's products are distributed primarily in North America, Europe, and select markets in Asia. Coefficient Bio generates revenue through a multifaceted business model that encompasses direct sales and strategic partnerships.

The company engages in B2B transactions, supplying its innovative bioproducts to agricultural firms and healthcare providers, as well as exploring subscription models for ongoing product support and updates. Flagship products are marketed through partnerships with distributors to enhance accessibility, with pricing structures designed to accommodate various client needs, ensuring both bulk and individual purchases are feasible for customers. Through these channels, Coefficient Bio aims to establish long-term relationships with clients while driving sustainable revenue growth. In the coming years, Coefficient Bio plans to introduce new products aimed at enhancing its existing offerings, though specific release dates have not been disclosed.

The company is also targeting expansion into additional markets across Europe and Asia by 2027 to increase its footprint in the biotechnology sector. The recent acquisition funding of USD 400 mn will be allocated towards enhancing research capabilities and accelerating product development, particularly in integrating artificial intelligence for better efficiency in biological research and clinical applications.